News
CLVLF
5.05
NaN%
--
Analysts Have Conflicting Sentiments on These Healthcare Companies: Clinuvel Pharmaceuticals (OtherCLVLF) and Telix Pharmaceuticals (OtherTLPPF)
TipRanks · 4d ago
Clinuvel Pharmaceuticals Reports Cessation of Securities in October 6-K Filing
TipRanks · 10/15 10:32
Clinuvel Pharmaceuticals Updates U.S. Investors on New and Ceased Securities via Form 6-K
TipRanks · 10/07 10:28
Clinuvel Pharmaceuticals Reports Expiry of 61,272 Performance Rights
TipRanks · 10/05 22:10
Clinuvel urges stability ahead of AGM as board warns against potential spill
TipRanks · 10/01 23:29
Clinuvel Shows Sustained Vitiligo Repigmentation with SCENESSE Combo Therapy
TipRanks · 10/01 02:19
Clinuvel Unveils ZEROKIN Single-Use Device for Controlled-Release Drug Delivery
TipRanks · 09/09 10:49
Clinuvel Unveils ZEROKIN Device to Target Growing Self-Injection Market
TipRanks · 09/07 23:53
Vanguard Drops Below Substantial Holder Threshold in Clinuvel Pharmaceuticals
TipRanks · 09/01 22:40
Analysts’ Top Healthcare Picks: Clinuvel Pharmaceuticals (CLVLF), AgomAb Therapeutics NV ADR (AGMB)
TipRanks · 08/31 12:20
Clinuvel Pharmaceuticals (CLVLF) was downgraded to a Hold Rating at Morgans
TipRanks · 08/31 00:35
MA Financial Group Sticks to Their Buy Rating for Clinuvel Pharmaceuticals (CLVLF)
TipRanks · 08/31 00:05
Clinuvel Pharmaceuticals (CLVLF) was downgraded to a Hold Rating at Canaccord Genuity
TipRanks · 08/30 23:37
Analysts Offer Insights on Healthcare Companies: Polynovo (OtherCALZF), Clinuvel Pharmaceuticals (OtherCLVLF) and Impedimed Limited (OtherIPDQF)
TipRanks · 08/27 23:40
Clinuvel Pharmaceuticals Limited GAAP EPS of A$0.67, revenue of A$94.02M
Seeking Alpha · 08/27 09:28
Clinuvel Weighs Nasdaq-Only Listing as Headquarters Shift to U.S.
TipRanks · 08/27 02:47
Clinuvel Flags Key Risks as It Builds U.S.-Led Expansion
TipRanks · 08/27 02:47
Clinuvel Confirms ASX Governance Compliance With 2026 Appendix 4G Filing
TipRanks · 08/27 02:47
Clinuvel Affirms ASX Governance Compliance and Highlights Diversity Gains
TipRanks · 08/27 02:38
Clinuvel Declares AUD 0.05 Dividend for FY2026
TipRanks · 08/27 02:38
More
Webull provides a variety of real-time CLVLF stock news. You can receive the latest news about Clinuvel Pharma through multiple platforms. This information may help you make smarter investment decisions.
About CLVLF
Clinuvel Pharmaceuticals Limited is a specialty pharmaceutical company. It is focused on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening, acute disorders, as well as healthcare solutions for specialized populations. Its lead therapy, SCENESSE (afamelanotide 16mg), is approved for commercial distribution in Europe, the United States of America, Israel, and Australia as the first systemic photoprotective drug for the prevention of phototoxicity (anaphylactoid reactions and burns) in adult patients with erythropoietic protoporphyria (EPP). It has operations in Europe, Singapore, and the United States of America. It develops and manufactures NEURACTHEL (adrenocorticotropic hormone) in different formulations, to target neurological, endocrinological, and degenerative disorders. Its pharmaceutical product, PRENUMBRA, has been developed, and its use is to be expanded in the clinic from stroke to Parkinson's.